Table 1 Baseline characteristics of K-ROAD and ADNI cohorts
From: Biomarker-integrated prognostic stagings for Alzheimer’s Disease
Variables | K-ROAD | ADNI total (N = 290) | |||
|---|---|---|---|---|---|
CU (N = 224) | MCI (N = 779) | Dementia (N = 260) | Total (N = 1263) | ||
Age, years | 71.0 ± 8.0 | 72.4 ± 7.8 | 70.7 ± 8.8 | 71.8 ± 8.1 | 73.7 ± 7.1 |
Female, n (%) | 144 (64.3) | 480 (61.6) | 166 (63.8) | 790 (62.5) | 142 (49.0) |
APOE ε4 carriers, n (%) | 70 (31.2) | 350 (44.9) | 150 (57.7) | 570 (45.1) | 97 (33.4) |
Education years | 10.5 ± 4.7 | 10.8 ± 4.7 | 10.2 ± 4.9 | 10.6 (4.7) | 16.4 ± 2.6 |
Clinical diagnosis CU/MCI/dementia, n (%) | - | - | - | 224 (17.7)/779 (61.7)/260 (20.6) | 160 (55.2)/118 (40.7)/12 (4.1) |
Aβ PET positivity, n (%) | 81 (36.2) | 466 (59.8) | 219 (84.2) | 766 (60.6) | 50 (44.6) |
MRI Hippocampal volume, mm3 | 2945.9 ± 597.9 | 2614.8 ± 546.0 | 2300.8 ± 536.8 | 2608.9 ± 588.1 | 3858.3 ± 506.4 |
Plasma Aβ42/40 | 0.06 ± 0.01 | 0.06 ± 0.02 | 0.06 ± 0.01 | 0.06 ± 0.02 | - |
Plasma pTau181, pg/ml | 6.7 ± 5.8 | 8.2 ± 7.4 | 10.3 ± 9.8 | 8.4 ± 7.8 | - |
Plasma pTau217, pg/ml | 0.5 ± 0.4 | 0.8 ± 0.6 | 1.1 ± 0.8 | 0.8 ± 0.6 | 0.4 ± 0.3a |
Plasma pTau231, pg/ml | 8.9 ± 4.1 | 10.6 ± 5.5 | 12.5 ± 5.4 | 10.7 ± 5.4 | - |
Plasma GFAP, pg/ml | 112.0 ± 54.3 | 156.0 ± 135.9 | 182.7 ± 79.0 | 153.7 ± 117.0 | 157.3 ± 90.1a |
Plasma NfL, pg/ml | 25.2 ± 11.9 | 32.6 ± 26.4 | 36.1 ± 30.8 | 32.0 ± 25.7 | - |
